Findings for genetically proxied ACE inhibition and colorectal cancer risk were replicated in an independent sample of 1,571 colorectal cancer cases and 120,006 controls of European ancestry in the Finngen consortium (1.40, 95% CI 1.02 to 1.92; P = 0.035). The gene discussed is ACE; the disease is colorectal cancer.